Altimmune, Inc. SEC filings ALT
Altimmune, Inc. has 1,005 filings in SEC EDGAR's recent list, going back to Jan 31, 2011. Its latest annual report, Form ARS, was filed on Mar 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (new debt). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Dec 5, 2025 | — |
| CORRESP | Letter to the SEC | Dec 3, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 19, 2025 | — |
| CORRESP | Letter to the SEC | Aug 12, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 8, 2025 | — |
| EFFECT | Filing | Mar 13, 2025 | — |
| CORRESP | Letter to the SEC | Mar 11, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 5, 2025 | — |
| CT ORDER | Filing | Nov 29, 2022 | — |
| EFFECT | Filing | Jan 11, 2021 | — |
| CORRESP | Letter to the SEC | Jan 7, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 7, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 22, 2019 | — |
| PRER14A | Filing | Aug 19, 2019 | — |
| CORRESP | Letter to the SEC | Aug 19, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 16, 2019 | — |
| UPLOAD | Letter from the SEC | Apr 15, 2019 | — |
| EFFECT | Filing | Apr 12, 2019 | — |
| CORRESP | Letter to the SEC | Apr 11, 2019 | — |
| CORRESP | Letter to the SEC | Apr 11, 2019 | — |
| CT ORDER | Filing | Oct 4, 2018 | — |
| POS EX | Filing | Sep 28, 2018 | — |
| EFFECT | Filing | Sep 27, 2018 | — |
| CORRESP | Letter to the SEC | Sep 27, 2018 | — |
| CORRESP | Letter to the SEC | Sep 27, 2018 | — |
| UPLOAD | Letter from the SEC | Aug 8, 2018 | — |
| CT ORDER | Filing | Oct 26, 2017 | — |
| NT 10-Q | Filing | Aug 10, 2017 | Jun 30, 2017 |
| CERTNAS | Auto-generated paper document | May 5, 2017 | — |
| 25 | Filing | May 5, 2017 | — |
| 8-A12B | Filing | May 4, 2017 | — |
| 425 | Filing | May 3, 2017 | — |
| 425 | Filing | Apr 27, 2017 | — |
| 425 | Filing | Apr 27, 2017 | — |
| EFFECT | Filing | Apr 6, 2017 | — |
| CORRESP | Letter to the SEC | Apr 6, 2017 | — |
| UPLOAD | Letter from the SEC | Apr 5, 2017 | — |
| EFFECT | Filing | Mar 31, 2017 | — |
| CORRESP | Letter to the SEC | Mar 31, 2017 | — |
| CORRESP | Letter to the SEC | Mar 31, 2017 | — |
| CORRESP | Letter to the SEC | Mar 29, 2017 | — |
| 425 | Form 8-k | Mar 29, 2017 | — |
| CORRESP | Letter to the SEC | Mar 16, 2017 | — |
| 425 | Form 8-k | Mar 14, 2017 | — |
| UPLOAD | Letter from the SEC | Mar 2, 2017 | — |
| 425 | Filing | Feb 13, 2017 | — |
| 425 | Form 8-k | Feb 1, 2017 | — |
| 425 | 8-k | Jan 19, 2017 | — |
| 8-A12B | Filing | Nov 25, 2015 | — |
| CT ORDER | Filing | Mar 20, 2015 | — |
| CT ORDER | Filing | Nov 25, 2014 | — |
| EFFECT | Filing | May 30, 2014 | — |
| CT ORDER | Filing | Apr 14, 2014 | — |
| 425 | Form 8-k | Nov 29, 2013 | — |
| 425 | 8-k | Nov 27, 2013 | — |
| 425 | 8-k | Nov 19, 2013 | — |
| 425 | Form 8-k | Nov 7, 2013 | — |
| 425 | 8-k | Nov 4, 2013 | — |
| CT ORDER | Filing | Oct 31, 2013 | — |
| EFFECT | Filing | Oct 29, 2013 | — |
| CORRESP | Letter to the SEC | Oct 29, 2013 | — |
| CORRESP | Letter to the SEC | Oct 22, 2013 | — |
| UPLOAD | Letter from the SEC | Oct 16, 2013 | — |
| CORRESP | Letter to the SEC | Oct 10, 2013 | — |
| 425 | Form 8-k | Oct 8, 2013 | — |
| UPLOAD | Letter from the SEC | Oct 1, 2013 | — |
| 425 | 8-k | Sep 11, 2013 | — |
| 425 | Form 8-k | Sep 10, 2013 | — |
| 425 | Current report | Sep 9, 2013 | — |
| 425 | Current report | Sep 9, 2013 | — |
| 425 | Form 8-k | Sep 9, 2013 | — |
| 425 | 8-k | Sep 6, 2013 | — |
| 425 | Form 8-k | Aug 8, 2013 | — |
| 425 | Form 8-k | Aug 7, 2013 | — |
| 425 | 8-k | Aug 1, 2013 | — |
| DEFR14A | Filing | May 9, 2013 | — |
| CT ORDER | Filing | Apr 18, 2013 | — |
| DEFR14A | Form defr14a | May 17, 2012 | — |
| EFFECT | Filing | Sep 21, 2011 | — |
| EFFECT | Filing | Jul 27, 2011 | — |
Showing 80 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ALT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Morristown, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1326190
- Former names
- PHARMATHENE, INC (until May 3, 2017); HEALTHCARE ACQUISITION CORP (until Oct 15, 2007)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.